Joseph Philip

Joseph Philip

Auto-generated profile, based on publicly available information

Joseph Philip

Department of Transfusion Medicine, Armed Forces Medical College, Pune, Maharashtra, India

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Asian Journal of Transfusion Science
Verified
Journal Article
Open access
PDF file
JPJoseph Philip
Joseph Philip
RSRavi S Sarkar
Ravi S Sarkar
APAmardeep Pathak
Amardeep Pathak
Introduction: Apheresis procedures [Plateletpheresis, Plasmapheresis/ Therapeutic Plasma Exchange (TPE), & Peripheral Blood Stem Cell Collection (PBSC)] are usually well tolerated. Occasionally, Adverse Events (AEs) of variable severity may occur during or after the procedure. AEs that occur in Donors/Patients are divided into local reactions and systemic reactions. Materials and Methods: A total of 3,367 apheresis procedures were performed, out of which 3,120 were plateletpheresis procedures, and out of which 1,401 were on Baxter CS 3000 & 1,719 were on Haemonetics MCS+ cell separators. Rest of 247 TPE & PBSC procedures were done on Haemonetics MCS+ cell separators. Results: 90 AEs were reported in relation to the 3,367 procedures. Out of 90 AEs, 85 AEs (94%) were associated with plateletpheresis (n = 3,120) and 05 AEs (06%) with TPE & PBSC (n = 247). The rate of vascular injury (VI), Citrate reaction (CR), and Presyncopal/Syncopal (PS/S) in plateletpheresis was 1.6% (52/3,120), 0.96% (30/3,120), and 0.096% (03/3,120), respectively. The rate of CR in TPE and PBSC was 1.23% (02/162) and 2.3% (02/85), respectively. The rate of PS/S in PBSC was 1.17% (01/85). AEs for Plateletpheresis, TPE & PBSC were 2.7% (85/3,120), 1.23% (02/162), and 3.5% (03/85), respectively. VI, CR, and PS/S were mostly of mild intensity. Both cell separators were equally safe, when AEs associated with plateletpheresis were compared with each other; 2.8% on CS 3000 & 2.6% on MCS+. Conclusion: Apheresis procedures performed on cell separators are safe, with a low incidence of significant AEs. No significant difference was noted in AEs among the two cell separators studied.

1 January 2014 in Asian Journal of Transfusion Science
Verified
Journal Article
Open access
PDF file
JPJoseph Philip
Joseph Philip
RSRs Sarkar
Rs Sarkar
NJNeelesh Jain
Neelesh Jain
Context: Vasovagal reactions (VVRs) in blood donors. Aim: To find an association of age, sex, donation status, weight, total blood volume and volume of blood collected with occurrence of immediate VVR. Settings and Design: Retrospective single-centre study. Materials and Methods: The study was conducted from March 2000 to November 2010 at a tertiary care blood transfusion centre. All VVRs with or without syncope occurring during or at the end of donation were noted. Statistical Analysis Used: For qualitative association, c 2 -test was used. Unpaired 't' test was used for assessing difference between two groups with respect to VVR status. Simultaneous impact of all risk factors was assessed using multivariate logistic regression analysis. The data entry software SPSS (version 17.0) was used for statistical analysis. A P-value <0.05 was considered statistically significant. Results: Overall 1085 VVRs were reported in relation to 88,201 donations, resulting in an overall VVR rate of 1.23%, that is, an incidence of 1 in every 81 donations. Donors with low blood volume, first-time donors, with low weight and female donors had higher absolute donation VVR rates than other donors. Conclusions: Donation-related vasovagal syncopal reactions are a multifactorial process determined largely by weight, age, first-time donor status and total blood volume. Our study reinforces the fact that blood donation is a very safe procedure, which could be made even more event-free by following certain friendly, reassuring practices and by ensuring strict pre-donation screening procedures.

6 October 2020 in ASAIO Journal
Verified
Journal Article
Closed access
DMDesiree S. Machado
Desiree S. Machado
CGCynthia Garvan
Cynthia Garvan
JPJoseph Philip
Joseph Philip
DHDonald Harrington
Donald Harrington
Bruce Davis SpiessBruce Davis Spiess
Bruce Davis Spiess
MBMark S. Bleiweis
Mark S. Bleiweis
We retrospectively compared anticoagulation with heparin and bivalirudin for 32 consecutive children under 18 years old during extracorporeal membrane oxygenation (ECMO) in our pediatric cardiac intensive care unit (PCICU). Between September 2015 and January 2018, 14 patients received heparin, 13 venoarterial (VA), and 1 venovenous (VV). From February 2018 to September 2019, 18 received bivalirudin (all VA). The mean (standard deviation [SD]) percentage of time with therapeutic activated partial thromboplastin time and activated clotting time was bivalirudin 54 (14%) and heparin 57 (11%), p = 0.4647, and percentage of time supratherapeutic was bivalirudin 18 (10%) and heparin 27 (12%), p = 0.0238. Phlebotomy-associated blood loss per hour of ECMO was double in the heparin compared with bivalirudin group 1.08 ml/h (0.20 ml/h), compared with 0.51 ml/h (0.07 ml/h), p = 0.0003, as well as interventions to control bleeding. Packed red blood cell (PRBC) transfusions significantly correlated with higher blood loss in the heparin group (Pearson correlation coefficient = 0.49, p = 0.0047). Overall amount of blood product utilization was not different between the groups. Survival to ECMO decannulation was 89% for bivalirudin and 57% for heparin, p = 0.0396, although 6 month survival was not significantly different (67% versus 57%, p = 0.5809). Heparin may increase the need for PRBC transfusions and strategies to attenuate bleeding when compared with bivalirudin for children receiving ECMO in PCICU.

1 July 2013 in Medical Journal Armed Forces India
Verified
Journal Article
Open access
SKSatish Kumar
Satish Kumar
RGR.M. Gupta
R.M. Gupta
SSSourav Sen
Sourav Sen
RSR.S. Sarkar
R.S. Sarkar
JPJ. Philip
J. Philip
SSS.H. Sumathi
S.H. Sumathi
Human parvovirus B19 is an emerging transfusion transmitted infection. Although parvovirus B19 infection is connected with severe complications in some recipients, donor screening is not yet mandatory. To reduce the risk of contamination, plasma-pool screening and exclusion of highly viraemic donations are recommended. In this study the prevalence of parvovirus B19 in healthy blood donors was detected by ELISA. A total of 1633 samples were screened for IgM and IgG antibodies against parvovirus B19 by ELISA. The initial 540 samples were screened for both IgM and IgG class antibodies and remaining 1093 samples were screened for only IgM class antibodies by ELISA. Net prevalence of IgM antibodies to human parvovirus B19 in our study was 7.53% and prevalence of IgG antibodies was 27.96%. Dual positivity (IgG and IgM) was 2.40%. The seroprevalence of human parvovirus B19 among blood donor population in our study is high, and poses an adverse transfusion risk especially in high-risk group of patients who have no detectable antibodies to B19. Studies with large sample size are needed to validate these results.

1 October 2013 in Medical Journal Armed Forces India
Verified
Journal Article
Closed access
RSR.S. Sarkar
R.S. Sarkar
JPJoseph Philip
Joseph Philip
RMR.S. Mallhi
R.S. Mallhi
PYPramod Yadav
Pramod Yadav

1 July 2015 in Medical Journal Armed Forces India
Verified
Journal Article
Closed access
TCT. Chatterjee
T. Chatterjee
JPJ. Philip
J. Philip
VNVelu Nair
Velu Nair
RMR.S. Mallhi
R.S. Mallhi
HSHemant Sharma
Hemant Sharma
ABA.K. Biswas
A.K. Biswas